FDA approves oral therapy for Grade 2 IDH-mutant glioma
Drug Discovery World
AUGUST 8, 2024
They are not curable with current therapies and without treatment they continue to grow and infiltrate normal brain tissue. We are proud to deliver this first-of-its-kind therapy to patients in need, and we remain committed to bringing innovative targeted therapies to people with cancer.”
Let's personalize your content